Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Figure 6.Mutational landscape of SMGs in TCGA LUAD cohort stratified by high-/low-risk subtypes. SMGs with significantly different mutation rate were highlighted in bold.